# Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

> **NCT03203525** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Advanced Malignant Neoplasm
- Colorectal Carcinoma Metastatic in the Liver
- Metastatic Malignant Neoplasm in the Liver
- Refractory Malignant Neoplasm

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride
- **DRUG:** Temsirolimus
- **PROCEDURE:** Tumor Treating Fields Therapy

## Key facts

- **NCT ID:** NCT03203525
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-23
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203525, "Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03203525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*